Argus
•
Oct 29, 2026
Biogen Inc.: Raising rating to BUY
Summary
Biogen Inc. is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for SMA and AD. The company also sells products that
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeAnalyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
